← board
ATHE
distress 2/10 · well-funded / low risk$4.680%today-29% from 52w high
Revenue
pre-revenue
Liquidity
$49M
Runway
4.3 yrs
Shares 1y
+1610%
Price & events
+43.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.4%
1D
-8.1%
1W
-5.6%
1M
+7.1%
3M
+31.8%
6M
-6.2%
1Y
+187.1%
2Y
-65.1%
5Y
-66.6%
All
Overview
- Market Cap
- $42.72B
- Volume
- 2.07K
- 52 Week Range
- $2.92 – $6.55
- Total Shares
- 9.13B
- Float Shares
- 288.05K
- Short %
- 0.22%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 1.78%
- RVOL
- 0.09x
- Beta
- -0.03
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 9,127,370,686 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $13 (+171% upside) · 3 analysts
- 2026-06-30Jones TradingBuy
- 2025-12-17Canaccord GenuitySpeculative Buy
- 2025-01-30Maxim GroupBuy
- 2024-12-12Maxim GroupBuy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.